HUWE1 and lymphoproliferative syndrome: Importantly, ARF-BP1 was expressed in human tumors and LCL expressing either wt or mutant p53 supporting the suggestion that it could be a therapeutic target in a variety of MYC-dependent lymphomas or EBV-dependent lymphoproliferative disorders regardless of p53 status [17].